Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): Preliminary Findings
Overview
Affiliations
Background: Although the popular drug 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") has been shown to damage brain serotonin (5-HT) neurons in animals, the fate and functional consequences of 5-HT neurons after MDMA injury are not known in humans. We investigated the long-term effects of MDMA use on cortical 5-HT neurons in humans and memory function, because brain 5-HT has been implicated in memory function.
Methods: Twenty-two recent MDMA users, 16 ex-MDMA users who had stopped using MDMA for more than 1 year, and 13 control subjects. The effects of MDMA use on cortical 5-HT neurons was studied by means of single-photon emission computed tomography with iodine 123-labeled 2beta-carbomethoxy-3beta-(4-iodophenyl) tropane ([(123)I]beta-CIT) by quantification of brain 5-HT transporter densities. Verbal memory performance was assessed with the Rey Auditory Verbal Learning Test.
Results: Mean cortical [(123)I]beta-CIT-labeled 5-HT transporter density was significantly lower in recent MDMA users than in controls (1.17 vs. 1.28 [-9%]) but not in ex-MDMA users (1.24 vs. 1.28 [-3%]). Recent and ex-MDMA users recalled significantly fewer words than did controls on the immediate recall (47.0 and 48.0 vs 60.0, respectively; P =.001) as well as the delayed recall (9.8 and 10.1 vs. 13.1, respectively; P =.003). Greater use of MDMA was associated with greater impairment in immediate verbal memory. However, memory performance was not associated with [(123)I]beta-CIT binding to cortical 5-HT transporters or duration of abstinence from MDMA.
Conclusion: The present study suggests that, while the neurotoxic effects of MDMA on 5-HT neurons in the human cortex may be reversible, the effects of MDMA on memory function may be long-lasting.
Tsai C, Chiu C, Kuo Y, Huang W, Yu T, Flores 2nd L Int J Mol Sci. 2022; 23(13).
PMID: 35806049 PMC: 9266335. DOI: 10.3390/ijms23137035.
Costa G, De Luca M, Piras G, Marongiu J, Fattore L, Simola N Neural Regen Res. 2019; 15(5):802-816.
PMID: 31719240 PMC: 6990793. DOI: 10.4103/1673-5374.268895.
Vegting Y, Reneman L, Booij J Psychopharmacology (Berl). 2016; 233(19-20):3473-501.
PMID: 27568200 PMC: 5021729. DOI: 10.1007/s00213-016-4396-5.
Klomp A, den Hollander B, de Bruin K, Booij J, Reneman L PLoS One. 2012; 7(10):e47524.
PMID: 23115651 PMC: 3480359. DOI: 10.1371/journal.pone.0047524.
Pharmacological treatment of anxiety disorders: current treatments and future directions.
Farach F, Pruitt L, Jun J, Jerud A, Zoellner L, Roy-Byrne P J Anxiety Disord. 2012; 26(8):833-43.
PMID: 23023162 PMC: 3539724. DOI: 10.1016/j.janxdis.2012.07.009.